GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
P

Precision BioSciences DTIL · USD

Health Care · US listing · 🇺🇸 United States

Compare

6.91

-2.68%

Close of 19 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

Price performance

Chart by TradingView, with its own licensed prices

Precision BioSciences — daily DTIL Delayed
Market value
$158.2m
Last close × shares
Volume
269.1k
Shares, 19 Nov 2026

About Precision BioSciences

From its filings with the US Securities and Exchange Commission

SEC filings

Precision BioSciences is based in Durham, North Carolina and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker DTIL. The SEC classifies its business as biological products, (no diagnostic substances). In the fiscal year to 31 December 2025, it reported revenue of $34.3m and a net loss of $45.7m. At that date it held total assets of $154.4m and shareholders' equity of $92.2m.

In its own words

We are a clinical stage gene editing company utilizing our novel proprietary ARCUS platform to concurrently develop two clinical-stage in vivo gene editing therapies. ARCUS differs from other technologies in the way it cuts, its smaller size, and its simpler structure. The ARCUS platform is used to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion (inserting DNA into gene to cause expression/add function), elimination (removing a genome, e.g. viral DNA), and excision (removing a large portion of a defective gene by delivering two ARCUS nucleases in a single adeno-associated virus (“AAV”)). We believe that the ARCUS platform’s key capabilities and differentiating characteristics can be leveraged for effective and safe therapeutic outcomes.

DNA carries the genetic instructions for all basic functions of a living cell. These instructions are encoded in four different molecules, called bases, which are strung together in specific sequences to form genes. Each gene is responsible for a specific function in a cell, and the complete set of genes in a cell, which can consist of tens of thousands of genes and billions of individual bases, is known as a genome. The complete genome sequence has been determined for many organisms, including humans. This allows scientists to identify specific genes and determine how their unique sequences contribute to a particular cellular function.

Quoted from its 10-K, filed 12 Mar 2026. Read the filing on SEC.gov ↗

More about Precision BioSciences →

How it makes its money

Revenue, year to 31 Dec 2025

  • Operating Segment $34.3m · 100.0%

Latest on Precision BioSciences

Our reporting

Next results

11 Mar 2027

Due on 11 Mar 2027. Analysts expect earnings of -0.90 a share.

Other Health Care listings

Scenario calculator

Try your own numbers. This is arithmetic, not a forecast.

Interactive

Gain or loss

—

Return

—

Leaves out fees, taxes and financing.

Frequently asked questions

What is Precision BioSciences's ticker?

Precision BioSciences trades as DTIL on its US listing, under ISIN US74019P2074.

What was Precision BioSciences's last closing price?

6.91 on 19 Nov 2026. The figure is in USD and is never converted.

When does Precision BioSciences next report results?

Results are expected on 11 Mar 2027, according to our data supplier.

Sources and methodology

Chart
TradingView
Close and company data
SEC filings and our data supplier
News
Our reporting

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.